NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

AMGN

AMGEN Inc

Apr 30 • 12:34PM ET

287.88

Dollar change -0.68
Percentage change -0.24	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: BIIB GILD REGN VRTX BMY MRNA ILMN PFE NBIX ABBV

| Held by: VTI VOO QQQ SCHD SPY IVV DIA VTV XLV VIG

Scroll to Statements

Index	DJIA, NDX, S&P 500	P/E	38.15	EPS (ttm)	7.55	Insider Own	0.23%	Shs Outstand	536.90M	Perf Week	3.59%
Market Cap	154.78B	Forward P/E	13.39	EPS next Y	21.51	Insider Trans	-6.08%	Shs Float	536.43M	Perf Month	-7.60%
Income	4.09B	PEG	8.87	EPS next Q	4.27	Inst Own	79.19%	Short Float	2.71%	Perf Quarter	2.20%
Sales	33.23B	P/S	4.66	EPS this Y	4.12%	Inst Trans	-0.07%	Short Ratio	4.57	Perf Half Y	-9.18%
Book/sh	10.95	P/B	26.30	EPS next Y	4.11%	ROA	4.33%	Short Interest	14.54M	Perf Year	6.63%
Cash/sh	22.27	P/C	12.93	EPS next 5Y	4.30%	ROE	67.55%	52W Range	253.30 - 346.85	Perf YTD	10.45%
Dividend Est.	9.73 (3.38%)	P/FCF	14.89	EPS past 5Y	-10.10%	ROI	6.48%	52W High	-17.00%	Beta	0.50
Dividend TTM	9.13 (3.17%)	Quick Ratio	0.95	Sales past 5Y	7.57%	Gross Margin	66.05%	52W Low	13.65%	ATR (14)	8.91
Dividend Ex-Date	May 16, 2025	Current Ratio	1.26	EPS Y/Y TTM	-39.39%	Oper. Margin	26.26%	RSI (14)	47.64	Volatility	2.58% 3.76%
Employees	28000	Debt/Eq	10.36	Sales Y/Y TTM	18.64%	Profit Margin	12.31%	Recom	2.39	Target Price	309.95
Option/Short	Yes / Yes	LT Debt/Eq	9.74	EPS Q/Q	-18.56%	Payout	119.05%	Rel Volume	0.43	Prev Close	288.56
Sales Surprise	2.31%	EPS Surprise	4.31%	Sales Q/Q	11.16%	Earnings	May 01 AMC	Avg Volume	3.18M	Price	287.88
SMA20	0.34%	SMA50	-4.59%	SMA200	-5.36%	Trades		Volume	673,896	Change	-0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Resumed	Cantor Fitzgerald	Neutral	$305
Dec-10-24	Resumed	BofA Securities	Underperform	$256
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$335
Oct-17-24	Initiated	Bernstein	Outperform	$380
Oct-14-24	Downgrade	Truist	Buy → Hold	$320 → $333
Sep-27-24	Initiated	Cantor Fitzgerald	Overweight	$405
Aug-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$320 → $335
May-03-24	Upgrade	William Blair	Mkt Perform → Outperform
May-03-24	Upgrade	Barclays	Underweight → Equal Weight	$230 → $300
Mar-28-24	Resumed	Raymond James	Mkt Perform
Feb-07-24	Downgrade	Leerink Partners	Outperform → Market Perform	$324 → $318
Dec-21-23	Upgrade	Daiwa Securities	Neutral → Buy	$264 → $320
Dec-19-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$286 → $326
Dec-12-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$256 → $300
Nov-09-23	Initiated	Deutsche Bank	Hold	$240
Nov-02-23	Upgrade	Truist	Hold → Buy	$260 → $320
Oct-20-23	Resumed	JP Morgan	Neutral	$265 → $270
Oct-17-23	Resumed	Morgan Stanley	Equal-Weight	$300
Oct-11-23	Resumed	BofA Securities	Neutral	$290

Show Previous Ratings

Apr-29-25 10:20AM	Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock? (Zacks)
10:01AM	Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know (Zacks)
09:12AM	AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs (Zacks)
06:42AM	Can Amgen Keep the Beat Streak Alive This Earnings Season? (Zacks)
06:32AM	The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron (Zacks)
06:20AM	Loading…
06:20AM	Should You Invest in the VanEck Biotech ETF (BBH)? (Zacks)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
04:01PM	AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS (PR Newswire)
12:08PM	Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? (Zacks)
11:41AM	Is Eli Lilly Stock a Portfolio Must-Have Pre-Q1 Earnings? (Revised) (Zacks)
11:20AM	Eli Lilly, Pfizer Risk Billions in Losses From Trump's 25% Pharma Tariffs (GuruFocus.com)
09:15AM	Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
09:10AM	3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income (Zacks)
07:45AM	Is Eli Lilly Stock a Portfolio Must-Have Pre-Q2 Earnings? (Zacks)
06:37AM	Amgen to invest $900m in Ohio manufacturing facility (Pharmaceutical Technology)
11:40PM	Loading…
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
06:00AM	What To Expect in the Markets This Week (Investopedia)
Apr-26-25 06:05PM	4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off (Motley Fool)
08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-25-25 05:06PM	Pharma reshoring: Amgen invests $900M in Ohio biotech facility (Yahoo Finance Video)
01:12PM	Amgen to expand Ohio biotech manufacturing plant (Reuters)
12:47PM	AMGEN ANNOUNCES $900 MILLION MANUFACTURING EXPANSION, CREATION OF 350 NEW JOBS IN OHIO (PR Newswire)
10:14AM	CytomX Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-24-25 04:22PM	Q1 Earnings Scorecard and Analyst Reports for Costco, American Express & Goldman Sachs (Zacks)
11:18AM	Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock? (Zacks)
10:01AM	Amgen (AMGN) Earnings Expected to Grow: Should You Buy? (Zacks)
07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-22-25 09:53AM	3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold (Motley Fool)
09:49AM	Is Amgen Inc. (AMGN) a Cheap NASDAQ Stock to Buy According to Hedge Funds? (Insider Monkey)
09:48AM	Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy (Investing.com)
05:50PM	Loading…
Apr-21-25 05:50PM	Amgen (AMGN) Stock Moves -1.3%: What You Should Know (Zacks)
02:24PM	Final Trades: Take-Two Interactive, Franco-Nevada, Amgen and the 10-Year Treasury (CNBC TV)
09:10AM	3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income (Zacks)
09:00AM	Is Most-Watched Stock Amgen Inc. (AMGN) Worth Betting on Now? (Zacks)
08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
Apr-18-25 09:40AM	Here's Why Amgen (AMGN) is a Strong Value Stock (Zacks)
Apr-17-25 06:18PM	Short Week Finishes with Netflix Q1 Beat (Zacks)
06:00PM	Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know (Zacks)
11:36AM	Wall Street Lunch: Obesity Pill Progress (Seeking Alpha)
10:12AM	Health Insurance Stocks Drop After UnitedHealth Forecast News (Investopedia)
09:45AM	Amgen Inc. (AMGN): Among the Innovative Healthcare Stocks to Watch in 2025 (Insider Monkey)
08:56AM	2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever (Motley Fool)
08:15AM	Amgen: The Biotech That Knows How To Make Money (Seeking Alpha)
08:03AM	Here's How You Should Play JNJ Stock After Q1 Earnings Beat (Zacks)
06:20AM	Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now? (Zacks)
06:20AM	Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
07:05AM	Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip? (Zacks)
05:56AM	Leqembi finally secures EU clearance; Sandoz sues Amgen over Enbrel patents (BioPharma Dive)
Apr-15-25 11:20PM	Aristotle Global Equity Q1 2025 Commentary (Seeking Alpha)
11:14AM	JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal (Zacks)
Apr-14-25 09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
06:59AM	Sandoz challenges Amgens Enbrel patents in US antitrust lawsuit (Pharmaceutical Technology)
05:27AM	Amgens Phase III trial of Imdelltra meets primary endpoint for SCLC (Clinical Trials Arena)
01:12AM	Sandoz files U.S. antitrust lawsuit against Amgen over arthritis drug (Reuters)
Apr-13-25 02:12PM	DJD: Dividend And Value In Mega Caps (Seeking Alpha)
09:15AM	SCHD's Portfolio Shake-Up: What It Means For Investors (Rating Downgrade) (Seeking Alpha)
Apr-12-25 08:30AM	How To Buy Low And Sell High Consistently For Lifelong Wealth (Seeking Alpha)
Apr-11-25 06:00PM	Amgen (AMGN) Gains But Lags Market: What You Should Know (Zacks)
11:32AM	Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings (Zacks)
09:00AM	IMDELLTRA DEMONSTRATED SUPERIOR OVERALL SURVIVAL IN SMALL CELL LUNG CANCER (PR Newswire)
08:15AM	Warning For SCHD Investors: Tariffs Are A Major Risk (Seeking Alpha)
08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
06:20AM	Is First Trust Dow 30 Equal Weight ETF (EDOW) a Strong ETF Right Now? (Zacks)
03:13AM	Pharmas US manufacturing moment: Where companies are making the biggest moves (Pharma Voice)
03:13AM	Pharmas manufacturing moment: Where companies are making the biggest moves (Pharma Voice)
02:05AM	Aristotle Capital Value Equity Composite Q1 2025 Commentary (Seeking Alpha)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha)
11:13AM	Harbor Capital Factor U.S. Large Cap ETF Q4 2024 Commentary (Seeking Alpha)
05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks)
01:00AM	Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. (Barrons.com)
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks)
06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Apr-08-25 10:09AM	LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now? (Zacks)
09:00AM	Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know (Zacks)
06:20AM	Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar? (Zacks)
Apr-07-25 09:14AM	NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare (Zacks)
09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
08:37AM	Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes (Zacks)
06:20AM	Should You Invest in the iShares Biotechnology ETF (IBB)? (Zacks)
05:50AM	FDA grants breakthrough therapy status for Amgen's Uplizna to treat IgG4-RD (Pharmaceutical Business Review)
01:00AM	This Type of Cholesterol Is a Risk Factor for Heart Disease. Emerging Drugs from Lilly and Amgen Could Treat It. (Barrons.com)
Apr-06-25 06:44AM	3 Dividend Stocks to Buy and Hold for the Next Decade (Motley Fool)
Apr-05-25 08:30AM	2 Dividend Stocks to Buy Hand Over Fist in April (Motley Fool)
Apr-04-25 03:33PM	Tariffs Hit Retail And Tech: Who's Ready To Make A Deal (Seeking Alpha)
01:10PM	AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication (Zacks)
Apr-03-25 05:50PM	Amgen (AMGN) Rises As Market Takes a Dip: Key Facts (Zacks)
04:50PM	Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday (Motley Fool)
03:35PM	UPLIZNA (INEBILIZUMAB-CDON) IS NOW THE FIRST AND ONLY FDA-APPROVED TREATMENT FOR IGG4-RELATED DISEASE (PR Newswire)
02:49PM	US FDA approves Amgen's Uplizna as first treatment for rare immune disorder (Reuters)
02:01PM	Final Trades: Amgen, Sabra Health Care and Kinsale Capital Group (CNBC TV)
05:08AM	Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks (StockStory)
05:05AM	Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now (Motley Fool)
Apr-02-25 11:12AM	Why Ideaya Biosciences Is Down Despite Many Positives (Seeking Alpha)
09:52AM	TCW Relative Value Large Cap Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 12:05PM	Dogs Of The Dow Chase April's 'Safer' Buy (Seeking Alpha)
11:40AM	GILD or AMGN: Which Is the Better Value Stock Right Now? (Zacks)
09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
08:08AM	Beat the Market the Zacks Way: Amgen, Stride, Sea Limited in Focus (Zacks)
07:44AM	Nvidia, Other Techs Hurt Dow Jones, But These Names Outperformed In Q1 (Investor's Business Daily)

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Santos Esteban	EVP, Operations	Feb 19 '25	Option Exercise	156.35	8,711	1,361,965	80,257	Feb 21 08:07 PM
Santos Esteban	EVP, Operations	Feb 19 '25	Sale	292.84	8,711	2,550,903	71,546	Feb 21 08:07 PM
REESE DAVID M	EVP & Chief Technology Officer	Feb 19 '25	Option Exercise	156.35	8,711	1,361,965	70,858	Feb 21 08:06 PM
REESE DAVID M	EVP & Chief Technology Officer	Feb 21 '25	Sale	304.44	25,225	7,679,524	36,922	Feb 21 08:06 PM
REESE DAVID M	EVP & Chief Technology Officer	Feb 19 '25	Sale	293.22	8,711	2,554,224	62,147	Feb 21 08:06 PM
DAVID M REESE & JOAN I CHUCO-T	Officer	Feb 21 '25	Proposed Sale	304.44	25,225	7,679,524		Feb 21 04:27 PM
Miller Derek	SVP, Human Resources	Feb 19 '25	Option Exercise	156.35	1,524	238,277	10,068	Feb 20 08:59 PM
Miller Derek	SVP, Human Resources	Feb 19 '25	Sale	293.74	1,524	447,655	8,544	Feb 20 08:59 PM
Miller Derek	SVP, Human Resources	Feb 18 '25	Sale	292.56	500	146,279	8,544	Feb 20 08:59 PM
DEREK MILLER	Officer	Feb 19 '25	Proposed Sale	293.74	1,524	447,655		Feb 19 04:18 PM
DAVID REESE	Officer	Feb 19 '25	Proposed Sale	293.22	8,711	2,554,224		Feb 19 04:14 PM
Santos Esteban	Affiliate	Feb 19 '25	Proposed Sale	292.11	8,711	2,544,570		Feb 19 02:25 PM
DEREK MILLER	Officer	Feb 18 '25	Proposed Sale	292.56	500	146,279		Feb 18 04:10 PM
Gordon Murdo	EVP, Global Commercial Ops	Feb 11 '25	Sale	294.79	8,771	2,585,644	44,186	Feb 13 09:02 PM
Gordon Murdo	Officer	Feb 11 '25	Proposed Sale	295.30	8,771	2,590,076		Feb 11 03:01 PM
Graham Jonathan P	EVP & Gen. Counsel & Secy.	Feb 07 '25	Option Exercise	156.35	25,045	3,915,786	54,032	Feb 10 09:52 PM
Graham Jonathan P	EVP & Gen. Counsel & Secy.	Feb 07 '25	Sale	293.12	25,045	7,341,123	28,987	Feb 10 09:52 PM
Graham Jonathan P	Officer	Feb 07 '25	Proposed Sale	292.94	25,045	7,336,682		Feb 07 03:05 PM
Grygiel Nancy A.	SVP & CCO	Feb 05 '25	Sale	304.47	1,589	483,808	7,210	Feb 06 08:54 PM
Grygiel Nancy A.	Officer	Feb 05 '25	Proposed Sale	304.47	1,589	483,800		Feb 05 12:53 PM
Grygiel Nancy A.	SVP & CCO	May 03 '24	Sale	313.09	2,117	662,802	9,883	May 03 07:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AMGN

AMGEN Inc

Upgrade your FINVIZ experience